The Zhitong Finance App learned that French biotech company Valneva (VALN.US) raised its product sales guidelines on Wednesday. Currently, product sales in 2024 are expected to be between 160 million euros and 180 million euros, higher than the previous forecast of 150 million euros to 180 million euros. Furthermore, the company estimates total revenue for 2024 to be between €170 million and €190 million.

According to the data, Valneva's total revenue in 2023 was 153.7 million euros, lower than the market's 361.3 million euros, falling short of market expectations of 171.7 million euros; product sales were 144.6 million euros, higher than the 2022 114.8 million euros; sales of products excluding COVID-19 vaccines increased 63% year over year.